These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26341049)

  • 1. Albuterol Overuse: A Marker of Psychological Distress?
    Gerald JK; Carr TF; Wei CY; Holbrook JT; Gerald LB
    J Allergy Clin Immunol Pract; 2015; 3(6):957-62. PubMed ID: 26341049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma.
    Patel M; Pilcher J; Reddel HK; Qi V; Mackey B; Tranquilino T; Shaw D; Black P; Weatherall M; Beasley R;
    J Allergy Clin Immunol Pract; 2014; 2(6):751-8. PubMed ID: 25439367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
    Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
    Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
    Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
    BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications.
    Boccuzzi SJ; Wogen J; Roehm JB
    Clin Ther; 2000 Feb; 22(2):237-47. PubMed ID: 10743983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease.
    Dalonzo GE
    J Am Osteopath Assoc; 2004 Jul; 104(7):288-93. PubMed ID: 15293593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta
    Azzi EA; Kritikos V; Peters MJ; Price DB; Srour P; Cvetkovski B; Bosnic-Anticevich S
    BMJ Open; 2019 Aug; 9(8):e028995. PubMed ID: 31412998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults.
    Nowak R; Emerman C; Hanrahan JP; Parsey MV; Hanania NA; Claus R; Schaefer K; Baumgartner RA;
    Am J Emerg Med; 2006 May; 24(3):259-67. PubMed ID: 16635694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor disease control among insured users of high-dose combination therapy for asthma.
    Broder MS; Chang EY; Kamath T; Sapra S
    Allergy Asthma Proc; 2010; 31(1):60-7. PubMed ID: 20167146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence.
    Onyirimba F; Apter A; Reisine S; Litt M; McCusker C; Connors M; ZuWallack R
    Ann Allergy Asthma Immunol; 2003 Apr; 90(4):411-5. PubMed ID: 12722963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to asthma controller medication regimens.
    Stempel DA; Stoloff SW; Carranza Rosenzweig JR; Stanford RH; Ryskina KL; Legorreta AP
    Respir Med; 2005 Oct; 99(10):1263-7. PubMed ID: 16140227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy.
    Pearlman DS
    Ann Allergy Asthma Immunol; 1995 Aug; 75(2):180-4. PubMed ID: 7648385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modifiable risk factors for suboptimal control and controller medication underuse among children with asthma.
    Smith LA; Bokhour B; Hohman KH; Miroshnik I; Kleinman KP; Cohn E; Cortés DE; Galbraith A; Rand C; Lieu TA
    Pediatrics; 2008 Oct; 122(4):760-9. PubMed ID: 18829799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.
    Wenzel SE; Lumry W; Manning M; Kalberg C; Cox F; Emmett A; Rickard K
    Ann Allergy Asthma Immunol; 1998 Jun; 80(6):463-70. PubMed ID: 9647268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.